Breakthrough scan could replace kidney biopsies for fibrosis monitoring

NCT ID NCT06563765

ENROLLING_BY_INVITATION Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new PET/CT imaging method that uses a special dye to spot kidney scarring (fibrosis) in people with chronic kidney disease. The goal is to see if this scan can accurately measure fibrosis without needing a needle biopsy. 150 patients will be scanned, and the results will be compared to their biopsy samples. If it works, doctors could monitor kidney damage over time more safely and easily.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FAP-targeting PET/CT imaging agent (FAPI-04 and new FAP probe)
What this could lead to: If successful, this could provide a non-invasive, repeatable way to monitor kidney fibrosis, helping doctors track disease progression and guide treatment without repeated biopsies.
What could go wrong: This is an early imaging study, not a treatment trial. The new probe's accuracy in mild-to-moderate fibrosis is still being tested, and results may not change patient outcomes directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease renal fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD RENAL FIBROSIS

Contacts and locations

Locations

Peking University First Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.